Collaterals in STEMI patients: An uncommon but critical lifeline
Sign Up to like & getrecommendations! Published in 2020 at "Catheterization and Cardiovascular Interventions"
DOI: 10.1002/ccd.29208
Abstract: Angiographically visible collaterals are seen in a minority of STEMI patients, predominantly to the RCA and in patients with delays to reperfusion. Patients with visible collaterals were less likely to have cardiogenic shock and tended… read more here.
Keywords: collaterals stemi; stemi patients; uncommon critical; critical lifeline ... See more keywords
Fulminant acanthamoebic meningoencephalitis in immunocompetent patients: an uncommon entity.
Sign Up to like & getrecommendations! Published in 2018 at "British journal of neurosurgery"
DOI: 10.1080/02688697.2018.1485873
Abstract: We are reporting two patients of fatal and rapidly progressive amoebic encephalitis in immunocompetent host from poor socioeconomic status. Both these patient had acute neurological worsening preoperatively and did not respond to subsequent surgical decompression.… read more here.
Keywords: fulminant acanthamoebic; immunocompetent; meningoencephalitis immunocompetent; immunocompetent patients ... See more keywords
New data on clinical decisions in NSCLC patients with uncommon EGFR mutations
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Respiratory Medicine"
DOI: 10.1080/17476348.2017.1267569
Abstract: ABSTRACT Introduction: Non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor (EGFR) mutations together account for approximately 10% of all EGFR mutations. The most common of which being G719X, S768I, L861Q, and exon… read more here.
Keywords: egfr mutations; lux lung; uncommon egfr; new data ... See more keywords
NSCLC with uncommon EGFR mutations treated with atezolizumab plus bevacizumab and chemotherapy.
Sign Up to like & getrecommendations! Published in 2022 at "Lung cancer"
DOI: 10.1200/jco.2022.40.16_suppl.e21076
Abstract: OBJECTIVES For refractory NSCLC patients with EGFR mutations, recent studies have demonstrated a favorable response to the combination of anti-angiogenic therapy and checkpoint inhibition but included only very few patients with uncommon EGFR mutations for… read more here.
Keywords: egfr mutations; line; chemotherapy; uncommon egfr ... See more keywords